The March 31, 2007 issue of The Lancet published the finding of the Japan EPA Lipid Intervention Study (JELIS) that the omega-3 fatty acid eicosapentaenoic acid (EPA) found in fish oil could be used in addition to statin drugs to provide additional protection against coronary artery disease. The study is the first major long-term interventional trial to evaluate this effect.
Mitsuhiro Yokoyama of Kobe University Graduate School of Medicine and colleagues randomized 18,645 men and women with a total cholesterol of at least 6.5 micromoles per liter to receive 1800 milligrams EPA with a statin drug, or a statin drug only for a five year period during which major coronary events were noted. Serum cholesterol levels were measured at the beginning and conclusion of the trial.
At the end of an average 4.6 years of follow up, LDL cholesterol concentrations had decreased by an average of 25% in both groups. A 19 percent reduction in major coronary events occurred in the group that received EPA compared to those that received a statin only. Unstable angina and nonfatal events were similarly reduced.
“This study shows that EPA, at a dose of 1800 mg per day, is a very promising regimen for prevention of major coronary events, especially since EPA seems to act through several biological mechanisms," the authors conclude. "We need to investigate whether EPA is effective for prevention of major coronary events in hypercholesterolemic patients without or with coronary artery disease in other countries”.
“Compared with drugs, invasive procedures, and devices, modest dietary changes are low risk, inexpensive, and widely available," Dariush Mozaffarian of Harvard wrote in an accompanying commentary."The JELIS investigators should be commended, and their efforts should inspire additional clinical trials of the effects of fish oil and other dietary factors and habits on cardiovascular health”.
—D Dye
Mitsuhiro Yokoyama of Kobe University Graduate School of Medicine and colleagues randomized 18,645 men and women with a total cholesterol of at least 6.5 micromoles per liter to receive 1800 milligrams EPA with a statin drug, or a statin drug only for a five year period during which major coronary events were noted. Serum cholesterol levels were measured at the beginning and conclusion of the trial.
At the end of an average 4.6 years of follow up, LDL cholesterol concentrations had decreased by an average of 25% in both groups. A 19 percent reduction in major coronary events occurred in the group that received EPA compared to those that received a statin only. Unstable angina and nonfatal events were similarly reduced.
“This study shows that EPA, at a dose of 1800 mg per day, is a very promising regimen for prevention of major coronary events, especially since EPA seems to act through several biological mechanisms," the authors conclude. "We need to investigate whether EPA is effective for prevention of major coronary events in hypercholesterolemic patients without or with coronary artery disease in other countries”.
“Compared with drugs, invasive procedures, and devices, modest dietary changes are low risk, inexpensive, and widely available," Dariush Mozaffarian of Harvard wrote in an accompanying commentary."The JELIS investigators should be commended, and their efforts should inspire additional clinical trials of the effects of fish oil and other dietary factors and habits on cardiovascular health”.
—D Dye
